|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 579 DKK | +1.40% |
|
-2.69% | +24.84% |
| Apr. 22 | U.S. Futures, European Stocks Rise | DJ |
| Apr. 16 | GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments | MT |
NKT A/S reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 2,598.6 million compared to EUR 2,112.1 million a year ago. Net income was EUR 124.3 million compared to EUR 62.4 million a year ago.
Basic earnings per share from continuing operations was EUR 2.2. Diluted earnings per share from continuing operations was EUR 2.1. Basic earnings per share was EUR 2.3. Diluted earnings per share was EUR 2.3.
| 1st Jan change | Capi. | |
|---|---|---|
| +24.84% | 4.45B | |
| +4.53% | 149B | |
| +34.66% | 130B | |
| +19.57% | 130B | |
| +12.90% | 62.82B | |
| +7.65% | 41.04B | |
| +94.65% | 35B | |
| +6.26% | 32.1B | |
| -9.78% | 32.1B | |
| +3.97% | 27.31B |
NKT A/S 
